Axonics Modulation Technologies

General Information


We are a medical technology company focused on the design, development, and commercialization of innovative and minimally invasive sacral neuromodulation, or SNM, solutions. SNM therapy is primarily used to treat patients with overactive bladder, or OAB, fecal incontinence, or FI, and urinary retention, or UR. Our proprietary rechargeable SNM system, or our r-SNM System, delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR.

Employees: 72
Founded: 2012
Contact Information
Address 26 Technology Drive, Irvine, CA 92618, US
Phone Number (949) 396-6322
Web Address
View Prospectus: Axonics Modulation Technologies
Financial Information
Market Cap $399.6mil
Revenues $0.14 mil (last 12 months)
Net Income $-24.2 mil (last 12 months)
IPO Profile
Symbol AXNX
Exchange NASDAQ
Shares (millions): 8.0
Price range $15.00 - $15.00
Est. $ Volume $120.0 mil
Manager / Joint Managers BofA Merrill Lynch/ Morgan Stanley
CO-Managers Wells Fargo Securities/ SunTrust Robinson Humphrey
Expected To Trade: 10/31/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change